QuickView for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=8FB57D525B943DDE2BC82C8FA82B1448;jsessionid=B43F2C6E2587AFA1F323AF2C026CCC2C;jsessionid=8314D55019A804A6CD08EA3FBE926F81;jsessionid=6E13A01030F3072791723FDB53EDD05E;jsessionid=D98F71D78EA395948FE5901879CA7FCE (gene)

1. Thymic stroma and TFII-I: towards new targeted therapies.
2. Proteomic analysis of SRF associated transcription complexes identified TFII-I as modulator of SRF f…
3. Structural basis for evolutionarily conserved interactions between TFIIS and Paf1C.
4. The TFIIS N-terminal domain (TND): a transcription assembly module at the interface of order and dis…
5. Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII.

There were no clinical trials for TFS-II;jsessionid=FD9D07EA4FEA2E9D62FC365AA7DE59D3;jsessionid=86A2AA8A39E51C0F450049D37E597C04;jsessionid=8FB57D525B943DDE2BC82C8FA82B1448;jsessionid=B43F2C6E2587AFA1F323AF2C026CCC2C;jsessionid=8314D55019A804A6CD08EA3FBE926F81;jsessionid=6E13A01030F3072791723FDB53EDD05E;jsessionid=D98F71D78EA395948FE5901879CA7FCE